Deferiprone - PharmaKB

Ferriprox(deferiprone)

Deferiprone, Ferriprox (deferiprone) is a small molecule pharmaceutical. Deferiprone was first approved as Ferriprox on 1999-08-25. It is used to treat iron overload in the USA. It has been approved in Europe to treat beta-thalassemia and iron overload.

Download report

Favorite

Events Timeline

Commercial

Clinical

Drug

Target

Variants

Financial

Trends

Safety

Events Timeline

YTD

Max

Events

FDA approval date

EMA approval date

Patent expiration date

Study first post date

Last update post date

Start date

Primary completion date

Completion date

Results first post date

Mock data
Subscribe for the real data

Commercial

Therapeutic Areas

Therapeutic Area	MeSH
hemic and lymphatic diseases	D006425
hereditary congenital and neonatal diseases and abnormalities	D009358
nutritional and metabolic diseases	D009750

Trade Name

FDA

EMA

Deferiprone, Ferriprox (discontinued: Ferriprox)

Drug Products

FDA

EMA

New Drug Application (NDA)

Abbreviated New Drug Application (ANDA)

Deferiprone

Tradename	Company	Number	Date	Products
FERRIPROX	Chiesi Farmaceutici	N-021825 RX	2011-10-14	2 products, RLD
FERRIPROX	Chiesi Farmaceutici	N-208030 RX	2015-09-09	1 products, RLD, RS
FERRIPROX	Chiesi Farmaceutici	N-212269 RX	2020-05-19	1 products, RLD, RS

Show 1 discontinued

Labels

FDA

EMA

Brand Name	Status	Last Update
deferiprone	ANDA	2025-12-15
ferriprox	New Drug Application	2025-05-22

Indications

FDA

EMA

Indication	Ontology	MeSH	ICD-10
iron overload	—	D019190	—

Agency Specific

FDA

EMA

Expiration	Code
DEFERIPRONE, FERRIPROX, CHIESI
2028-04-30	ODE-417, ODE-418, ODE-419, ODE-420, ODE-421
2024-04-30	I-859

Patent Expiration

Patent	Expires	Flag	FDA Information
Deferiprone, Ferriprox, Chiesi
10780055	2038-10-25	DP	U-3083
10940115	2038-10-25	DP	U-3083
10940116	2038-10-25	DP
11357731	2038-10-25		U-3083
11458103	2038-10-25	DP
11723874	2038-10-25		U-3083
8703156	2029-10-26	DP	U-3083

ATC Codes

V: Various drug classes in atc

— V03: All other therapeutic products

— V03A: All other therapeutic products

— V03AC: Iron chelating agents

— V03AC02: Deferiprone

HCPCS

No data

Clinical

Clinical Trials

2626 clinical trials

View more details

Mock data
Subscribe for the real data

Indications Phases 4

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Non-small-cell lung carcinoma	D002289	—	—	175	298	128	3	84	598
Neoplasms	D009369	—	C80	282	195	14	3	42	421
Lung neoplasms	D008175	—	C34.90	90	148	40	1	63	300
Carcinoma	D002277	—	C80.0	61	142	30	1	41	235
Melanoma	D008545	—	—	94	89	8	3	18	167
Squamous cell carcinoma of head and neck	D000077195	—	—	53	86	21	1	12	141
Hepatocellular carcinoma	D006528	—	C22.0	36	60	12	2	31	125
Liver neoplasms	D008113	EFO_1001513	C22.0	29	46	13	1	30	109
Uterine cervical neoplasms	D002583	—	—	26	39	19	5	13	89
Papillomavirus infections	D030361	—	—	4	17	48	9	9	87

Show 61 more

Indications Phases 3

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Breast neoplasms	D001943	EFO_0003869	C50	58	74	18	—	19	143
Triple negative breast neoplasms	D064726	—	—	42	55	19	—	4	102
Neoplasm metastasis	D009362	EFO_0009708	—	54	51	14	—	4	98
Colorectal neoplasms	D015179	—	—	47	49	6	—	8	94
Renal cell carcinoma	D002292	EFO_0000376	—	46	49	14	—	6	92
Small cell lung carcinoma	D055752	—	—	32	48	9	—	11	85
Stomach neoplasms	D013274	EFO_0003897	C16	27	46	14	—	16	82
Squamous cell carcinoma	D002294	—	—	28	52	10	—	10	82
Head and neck neoplasms	D006258	—	—	32	38	10	—	7	66
Lymphoma	D008223	—	C85.9	32	35	4	—	3	62

Show 122 more

Indications Phases 2

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Sarcoma	D012509	—	—	13	20	—	—	2	27
Cutaneous malignant melanoma	D000096142	—	—	12	8	—	—	—	16
Wounds and injuries	D014947	—	T14.8	—	1	—	—	15	16
Syndrome	D013577	—	—	4	8	—	—	3	15
Neuroendocrine tumors	D018358	EFO_1001901	D3A.8	2	7	—	—	2	10
Gastrointestinal neoplasms	D005770	—	C26.9	3	5	—	—	4	10
Skin neoplasms	D012878	EFO_0004198	C44	7	4	—	—	—	9
T-cell lymphoma	D016399	—	—	5	6	—	—	1	9
Myelodysplastic syndromes	D009190	—	D46	5	4	—	—	—	9
Neoadjuvant therapy	D020360	—	—	1	5	—	—	2	8

Show 146 more

Indications Phases 1

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Inflammation	D007249	MP_0001845	—	1	—	—	—	4	5
Bites and stings	D001733	—	—	3	—	—	—	1	4
Neuroblastoma	D009447	EFO_0000621	—	1	—	—	—	3	4
Ureteral neoplasms	D014516	EFO_0003844	C66	3	—	—	—	—	3
Pleural effusion	D010996	—	J90	1	—	—	—	2	3
Pelvic neoplasms	D010386	—	—	2	—	—	—	—	2
Chordoma	D002817	EFO_0000334	—	1	—	—	—	1	2
Acute disease	D000208	—	—	1	—	—	—	1	2
Ascites	D001201	—	R18	1	—	—	—	1	2
Malignant pleural effusion	D016066	—	J91.0	1	—	—	—	1	2

Show 34 more

Indications Without Phase

Indication	MeSH	Ontology	ICD-10	Ph 1	Ph 2	Ph 3	Ph 4	Other	Total
Spinal cord injuries	D013119	EFO_1001919	—	—	—	—	—	11	11
Traumatic brain injuries	D000070642	—	S06	—	—	—	—	10	10
Osteoporosis	D010024	EFO_0003882	M81.0	—	—	—	—	9	9
Pain	D010146	EFO_0003843	R52	—	—	—	—	8	8
Brain injuries	D001930	—	S06.9	—	—	—	—	8	8
Hernia	D006547	—	K40-K46	—	—	—	—	7	7
Brain concussion	D001924	—	S06.0	—	—	—	—	5	5
Inguinal hernia	D006552	HP_0000023	K40	—	—	—	—	4	4
Intervertebral disc displacement	D007405	EFO_1001800	—	—	—	—	—	4	4
Pregnancy	D011247	EFO_0002950	Z33.1	—	—	—	—	4	4

Show 228 more

Epidemiology

Epidemiological information for investigational and approved indications

View more details

Drug

General

Drug common name	Deferiprone
INN	deferiprone
Description	Deferiprone is a member of the class of 4-pyridones that is pyridin-4(1H)-one substituted at positions 1 and 2 by methyl groups and at position 3 by a hydroxy group. A lipid-soluble iron-chelator used for treatment of thalassaemia. It has a role as an iron chelator and a protective agent.
Classification	Small molecule
Drug class	—
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)	Cc1c(O)c(=O)ccn1C